Lyell Immunopharma
Overview
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission\'s urgency. POSITION SUMMARY: The Senior Scientist, Analytical Development will be responsible for leading development of flowcytometry, molecular and cell-based assays for release and characterization of engineered T-cell products and analytics for process understanding. The successful candidate will be responsible for leading a group within Analytical Development and mentoring scientists, hands-on assay development and driving projects in close collaboration across TechOps and research. In this role you will work closely with other members of the analytical development team to develop strategy, conduct experiments, develop test methods, and assist in the tech transfer of analytical methodologies into a GMP manufacturing and QC testing facility. The successful candidate will have expertise in flowcytometry based assay development, experience with analytical testing methodologies and an understanding of the technological requirements to execute on testing and characterization needs of a cellular therapy company.
#J-18808-Ljbffr
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission\'s urgency. POSITION SUMMARY: The Senior Scientist, Analytical Development will be responsible for leading development of flowcytometry, molecular and cell-based assays for release and characterization of engineered T-cell products and analytics for process understanding. The successful candidate will be responsible for leading a group within Analytical Development and mentoring scientists, hands-on assay development and driving projects in close collaboration across TechOps and research. In this role you will work closely with other members of the analytical development team to develop strategy, conduct experiments, develop test methods, and assist in the tech transfer of analytical methodologies into a GMP manufacturing and QC testing facility. The successful candidate will have expertise in flowcytometry based assay development, experience with analytical testing methodologies and an understanding of the technological requirements to execute on testing and characterization needs of a cellular therapy company.
#J-18808-Ljbffr